Dr. Reddy's Laboratories arrives at its June 10 print with the same structural split that has defined this entire preview cycle — but the lending market has shifted materially since the last article.
The most notable change is in availability, which has jumped to 93% from the 62–63% range that held through most of last week. That is back near the 52-week high of 90.4% and a dramatic reversal from the sub-33% cycle lows of mid-May. Cost to borrow has continued drifting lower, now at 0.90% — down from the 1.07% spike seen ahead of the June 5 release, though still well above the sub-0.60% readings of late April. Shares short edged fractionally lower to 19.6 million on June 8, essentially flat on the week, and the one-month build remains steep at roughly 42%. The ORTEX short score eased slightly to 56.2, its lowest reading in two weeks but still running above mid-May levels. The message from the lending side is that the acute squeeze on the borrow pool has unwound, yet the underlying short position has not — sellers who built over the past month have held their ground.
Options traders remain as relaxed as they have been throughout this cycle. The put/call ratio edged up to 0.19 on June 9, marginally above recent lows but still well below its 20-day average of 0.28 and near the bottom of its 52-week range. That tilt toward calls suggests options participants are not pricing in meaningful downside from the print — a view that has persisted despite the elevated short interest running alongside it. The divergence between a crowded short book and unbothered options positioning is not new here; it has been the defining tension of this entire run-up.
The analyst backdrop carries a notable data point, though it requires context. HSBC upgraded RDY to Buy from Hold in June 2025, lifting its target to $16.90. The current price of $13.37 sits below that target, implying the bullish thesis has not yet been realised. Recent generic notes point to regulatory scrutiny around manufacturing compliance as the key bear argument, with margin sustainability the secondary concern. The stock has gained about 1% on both a one-day and one-month basis — a largely directionless drift that underscores the market's indecision heading into the release.
The print will test whether the entrenched short position is sitting on a genuine fundamental thesis around compliance and margins, or whether the borrow pool's rapid loosening signals that at least some of that conviction is already quietly unwinding.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
